Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc

Femme Max 99 ans
Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc MAJ Il y a 4 ans

First Extension (018-06(PL_3)): A Blinded Extension to 5 Years for: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium Second Extension (018-20(PL_1)): A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium Second Extension (018-21(PL_2)): An Open-Label 5-Year 2nd Extension to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium First Extension To assess the effect of treatment up to 5 years with odanacatib on the risk of morphometrically assessed vertebral fractures compared to placebo. To assess the effect of treatment up ...

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations